Tianjin Hematonosis Hospital
Tianjin, Tianjin Municipality, 30020, China
NCT Number: NCT02643901
This study is designed to access the tolerability and Pharmacokinetic/Pharmacodynamic (PK/PD) of single subcutaneous (SC) injection of GW003 in healthy subjects.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Tianjin, Tianjin Municipality, 30020, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
single SC injection
Time frame: up to day 21
To evaluate the safety and tolerance of single SC injection of GW003 in healthy subjects.
Time frame: up to 6 months after the trial
anti-GW003 was detected pre-dose and at the last visit,if there exist positive anti-GW003 antibody, another detected should be conducted 6 months after the trial.
Time frame: up to day 14
Time frame: up to day 14
Jiangsu T-Mab Biopharma Co.,Ltd
Industry
The Single-Dose Tolerability and PK/PD Study of Recombinant (Expressed by Pichia Pastoris) Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I) Fusion Protein for Injection (GW003) in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07192770
Behavior, Behavioral Symptoms
Ankara, Yenimahalle, Turkey (Türkiye)
View Trial DetailsNCT03102606
Chemotherapy-induced Neutropenia
Stanford, California, United States
View Trial DetailsNCT04345900
Chemotherapy-induced Neutropenia
Redlands, California, United States
View Trial DetailsNCT00837265
Chemotherapy-induced Neutropenia
View Trial Details